|

Lu-177-DOTATATE Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)2

Indications

  • Neuroendocrine Neoplasms2
  • Neuroendocrine Tumors2
  • Cancer2
  • Gastroenteropancreatico Tumors1
  • Paraganglioma1

Bethesda, Maryland2 trials

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center

Phase 1/2
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.